(67,198)(11,300)Net cash provided by (used in) investing activities
5,564,703(2,605,806)Cash flows from financing activities:Net proceeds from public offering of common stock
-14,917,059Net proceeds from exercise of warrants and options
207,0502,275,906Net cash provided by financing activities
207,05017,192,965Effect of exchange rate changes on cash and cash equivalents
(15,824)(28,674)Net increase in cash and cash equivalents
3,474,77713,076,418Cash and cash equivalents at beginning of period
6,063,5732,311,269Cash and cash equivalents at end of period
$9,538,350$15,387,687Supplemental disclosure of cash flow information:Cash paid during the period for interest
$57$-Cash paid (received) during the period for income taxes
24,074(248)Non-GAAP Financial Measures: The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies. Therefore, our non-GAAP financial measures may not be comparable to those used by other companies. We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.
We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for inte
|SOURCE Uroplasty, Inc.|
Copyright©2010 PR Newswire.
All rights reserved